Cohen & Steers: Still Bullish After Assessing Q2 Results And AUM Figures
CNS is still deserving of a Buy rating based on my analysis of the company's Q2 2024 financial and operating metrics. Cohen & Steers' actual revenue and non-GAAP adjusted EPS for the second quarter were largely consistent with the Wall Street analysts' expectations. There's the potential for CNS' AUM for the U.S. real estate strategy to grow, assuming rate cuts materialize.
CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series
Live video webcast with Chief Executive Officer, John Climaco, on Wednesday, June 17th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / July 16, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in the Virtual Investor Closing Bell Series on Wednesday, June 17, 2024 at 4:00 PM ET. As part of the event, Mr.
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
HOUSTON, TX / ACCESSWIRE / July 3, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 1,425,000 shares of common stock in a registered direct offering and warrants to purchase up to 1,425,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the "Offering") at a combined purchase price of $1.39 per share. The warrants issued pursuant to the concurrent private placement will have an exercise price of $1.26 per share, will be exercisable immediately following the date of issuance and will expire 5 years from the initial exercise date.
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
HOUSTON, TX / ACCESSWIRE / June 26, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 568,000 shares of common stock in a registered direct offering and warrants to purchase up to 568,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the "Offering") at a combined purchase price of $2.45 per share. The warrants issued pursuant to the concurrent private placement will have an exercise price of $2.32 per share, will be exercisable immediately following the date of issuance and will expire 5 years from the initial exercise date.
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
HOUSTON, TX / ACCESSWIRE / June 14, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 366,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase up to 366,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the "Offering") at a combined purchase price of $3.75 per share. The warrants issued pursuant to the concurrent private placement will have an exercise price of $3.62 per share, will be exercisable immediately following the date of issuance and will expire 5 years from the initial exercise date.
Cohen & Steers (CNS) May AUM Balance Rises on Upbeat Markets
Cohen & Steers (CNS) reports an improvement in the May 2024 AUM balance on solid market performance.
Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments
ACADIA Pharmaceuticals is a biopharmaceutical company specializing in CNS disorder treatments, with two successful FDA-approved commercial products, Nuplazid and Daybue. Nuplazid, indicated for Parkinson's disease psychosis, generates over $300 million in yearly cash flow, while Daybue, approved for Rett syndrome, had a successful launch. ACAD has a promising pipeline of drug candidates, including ACP-101 for Prader-Willi syndrome and ACP-204 for Alzheimer's disease psychosis, which could create additional revenue verticals.
CNS Pharmaceuticals Announces Reverse Stock Split
HOUSTON, TX / ACCESSWIRE / June 3, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-50 reverse split of its common stock, effective at 4:01 PM ET on June 4, 2024. Beginning on June 5, 2024, the Company's common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis under the trading symbol "CNSP", but will trade under the following new CUSIP number: 18978H300.
Rapport Therapeutics Seeks IPO For CNS Treatment Programs
Rapport Therapeutics, Inc. has filed for a $100 million IPO to develop treatment candidates for central nervous system and related disorders. The company's lead candidate, RAP-219, is being developed to treat Focal Epilepsy, peripheral nerve pain, and bipolar disorder. Rapport Therapeutics is backed by top-tier life science venture capital firms and has connections to Johnson & Johnson, so the IPO is one to watch.
Swiss National Bank Sells 6,100 Shares of Cohen & Steers, Inc. (NYSE:CNS)
Swiss National Bank trimmed its position in shares of Cohen & Steers, Inc. (NYSE:CNS – Free Report) by 10.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,300 shares of the asset manager’s stock after selling 6,100 shares during the quarter. Swiss National Bank owned 0.11% of Cohen & Steers worth $4,036,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds also recently made changes to their positions in CNS. Moody Aldrich Partners LLC lifted its holdings in Cohen & Steers by 39.5% during the fourth quarter. Moody Aldrich Partners LLC now owns 135,849 shares of the asset manager’s stock worth $10,288,000 after acquiring an additional 38,458 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Cohen & Steers by 4.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 672,011 shares of the asset manager’s stock worth $42,128,000 after purchasing an additional 30,924 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Cohen & Steers during the 3rd quarter worth approximately $1,881,000. EFG Asset Management North America Corp. acquired a new stake in Cohen & Steers during the 3rd quarter worth approximately $967,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Cohen & Steers by 5.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,754 shares of the asset manager’s stock valued at $1,193,000 after buying an additional 746 shares in the last quarter. Institutional investors and hedge funds own 51.47% of the company’s stock. Cohen & Steers Price Performance Shares of Cohen & Steers stock opened at $73.31 on Monday. The firm has a market cap of $3.71 billion, a price-to-earnings ratio of 28.53 and a beta of 1.45. The stock’s 50-day moving average is $72.05 and its 200-day moving average is $68.95. Cohen & Steers, Inc. has a one year low of $50.05 and a one year high of $78.58. Cohen & Steers (NYSE:CNS – Get Free Report) last released its earnings results on Thursday, April 18th. The asset manager reported $0.70 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.01). The firm had revenue of $122.71 million during the quarter, compared to the consensus estimate of $125.01 million. Cohen & Steers had a net margin of 26.27% and a return on equity of 36.67%. The company’s revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.76 EPS. Cohen & Steers Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 23rd. Shareholders of record on Monday, May 13th will be paid a $0.59 dividend. The ex-dividend date is Friday, May 10th. This represents a $2.36 annualized dividend and a yield of 3.22%. Cohen & Steers’s payout ratio is currently 91.83%. Wall Street Analysts Forecast Growth Separately, UBS Group lowered their price objective on shares of Cohen & Steers from $69.00 to $67.00 and set a “sell” rating for the company in a research report on Friday, April 12th. Read Our Latest Stock Report on CNS Insiders Place Their Bets In other news, Director Edmond D. Villani sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $72.99, for a total value of $291,960.00. Following the completion of the transaction, the director now owns 33,781 shares in the company, valued at approximately $2,465,675.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Richard P. Simon sold 6,942 shares of the business’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $71.76, for a total transaction of $498,157.92. Following the transaction, the director now directly owns 24,973 shares in the company, valued at $1,792,062.48. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Edmond D. Villani sold 4,000 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $72.99, for a total transaction of $291,960.00. Following the completion of the sale, the director now owns 33,781 shares of the company’s stock, valued at approximately $2,465,675.19. The disclosure for this sale can be found here. Insiders have sold 14,000 shares of company stock valued at $1,009,713 in the last three months. 47.60% of the stock is currently owned by corporate insiders. About Cohen & Steers (Free Report) Cohen & Steers, Inc is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to institutional investors, including pension funds, endowments, and foundations. It manages separate client-focused equity, fixed income, multi-asset, and commodity portfolios through its subsidiaries.
